Andrew Anzalone

Director, Head of Prime Editing Platform

‍Prime Medicine, Inc.

Director, Head of Prime Editing Platform

‍Prime Medicine, Inc.

#primeeditingtech #immunotherapies

#NorthAmerica

Andrew Anzalone is head of the prime editing platform at Prime Medicine, where he currently leads efforts to advance prime editing technologies for human therapeutic applications. Prior to joining Pri

Chantal Kuhn

Associate Director

‍Takeda Oncology

Associate Director

‍Takeda Oncology

#immunotherapies

#NorthAmerica

I'm an experienced immunologist passionate about development of new immunotherapies for cancer and autoimmunity.

Ed Sleeper

Ethics & Compliance Officer (U.S. & Europe)

‍HUTCHMED

Ethics & Compliance Officer (U.S. & Europe)

‍HUTCHMED

#Compliance #immunotherapies #immunology

#NorthAmerica

Ed is the Global Ethics & Compliance Officer for HUTCHMED International Corporation focused on the development of targeted therapies and immunotherapies for the treatment of cancer and immunological d

Robin Mansukhani

CEO

‍Deciduous Therapeutics

CEO

‍Deciduous Therapeutics

#immunotherapies #venturecapital

#NorthAmerica

CEO and Co-Founder of Deciduous Therapeutics, a venture backed startup developing novel immunotherapies to treat age related diseases.